Taxus Breezes Through Panel On Cypher Drag, Possibly Raising Data Bar

The FDA Circulatory System Devices Panel endorsed Boston Scientific's proposed ARRIVE 2,000-patient, five-year Taxus postmarket study with no additional conditions beyond proposals made by the company